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A B S T R A C T
Objectives: The objective of this study was to identify the epidemiological, clinical, and microbiological
factors affecting the outcome of peritoneal dialysis (PD)-associated peritonitis.
Methods: All patients with PD-associated peritonitis, cared for at the University Hospital of Heraklion
from 1990 to 2007, were retrospectively studied.
Results: A total of 247 episodes of PD-associated peritonitis occurring in 82 patients were evaluated. The
median age of patients was 68 years (range 10–92 years); 51 (62%) were males. There were 104 episodes
(42%) of Gram-positive peritonitis, 46 (19%) of Gram-negative peritonitis, 13 (5%) of polymicrobial
peritonitis, and 11 (4%) of fungal peritonitis. There were 64 (26%) complicated episodes. The latter
included 22 (8.9%) relapses, 13 (5.3%) repeated episodes, 18 (7.3%) catheter removals, and 11 (4.5%)
deaths. In multivariate analysis, the presence of a purulent exit-site infection (p < 0.001), peritoneal
dialysis efﬂuent cell count >100  106/l for more than 5 days (p < 0.001), use of antimicrobials during
the preceding 3 months (p < 0.05), and low serum total protein level on admission (p < 0.05) were
independent predictors of a complicated course.
Conclusions: Exit-site infection, more than 5 days with a peritoneal dialysis efﬂuent cell count
>100  106/l, prior use of antimicrobials, and low serum total protein level are potential predictors of
complicated PD-associated peritonitis and may distinguish high-risk cases.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Peritoneal dialysis (PD) is an important form of renal
replacement therapy for patients with end-stage renal disease
(ESRD). The percentage of ESRD patients maintained on chronic PD
is declining, due to the high incidence of peritonitis, which
represents a frequent complication and the main cause of
peritoneal catheter loss and termination of continuous ambulatory
peritoneal dialysis (CAPD).1 Usually after such an infection patients
are managed by hemodialysis.2–4
The identiﬁcation of risk factors, publication of guidelines,
development of new techniques, and the implementation of more
effective therapies have led to a reduction in the PD-associated
peritonitis incidence.5–7 However, this infection remains a
signiﬁcant cause ofmorbidity andmortality in patients undergoing* Corresponding author. Tel.: +30 2810 392359; fax: +30 2810 392847.
E-mail address: kofterid@med.uoc.gr (D.P. Kofteridis).
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.07.016PD.8,9 There have been few studies investigating risk factors that
could predict the outcome of this infection once it develops.10
The aim of this study was to identify epidemiological, clinical,
and microbiological factors affecting the severity and outcome of
PD-associated peritonitis.
2. Methods
This study was performed at the 650-bed University Hospital of
Heraklion, Crete, Greece. The records of all patients hospitalized
with PD-associated peritonitis between January 1990 and June
2007 were retrospectively reviewed.
The diagnosis was based on established criteria.8 Peritonitis
was deﬁned by the presence of cloudy PD efﬂuent with more than
100  106white blood cells (WBC)/l and aWBCdifferential ofmore
than 50% polymorphonuclear cells.5 Because the deﬁnition of PD-
associated peritonitis varied slightly during the long period of our
study, we considered eligible only patients who fulﬁlled the above
deﬁnition, irrespective of the time of diagnosis.ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Patient demographic and clinical data
Characteristics
Sex: male/female, n 51/31
Community: urban/rural, n 39/43
Age (years), mean  SD 64.1  16.2
Duration on dialysis (months), mean  SD 21.5  23.6
Co-morbidities, n (%)
Hypertension 48 (59)
Cardiovascular disease 45 (55)
Diabetes mellitus 26 (32)
Secondary hyperparathyroidism 16 (20)
Obstructive pulmonary disease 7 (9)
Autoimmune disease 6 (7)
Cancer 2 (2)
Causes of ESRD, n (%)
Diabetic nephropathy 23 (28)
Hypertensive nephrosclerosis 13 (16)
Glomerulonephritis 8 (10)
Polycystic kidney disease 7 (9)
Chronic pyelonephritis 5 (6)
Obstructive uropathy 5 (6)
Unknown 18 (22)
Other 3 (4)
Type of peritoneal dialysis, n (%)
Continuous ambulatory 31 (38)
Ambulatory 51 (62)
No of peritonitis episodes, n (%)
1 30 (37)
2 18 (22)
3–4 16 (19)
>5 18 (22)
Previous history of peritonitis, n (%)
Yes 31 (38)
No 51 (62)
ESRD, end-stage renal disease.
D.P. Kofteridis et al. / International Journal of Infectious Diseases 14 (2010) e489–e493e490The data extracted from the medical records included:
demographic characteristics such as age at time of peritonitis,
age at start of PD, sex, and cause of ESRD; underlying medical
conditions; type of PD (CAPD/ambulatory peritoneal dialysis
(APD)) and duration of PD therapy; data for each PD-associated
peritonitis episode, including symptom duration, number of
episodes, use of antimicrobials during the three preceding months
(we were able to retrieve this information since all patients
suffered from a chronic condition and were under continual and
intensive observation), time interval between two episodes,
presence of exit-site infection (erythema or drainage from the
exit-site or both), causative organisms, type and duration of
treatment, and length of hospital stay; laboratory examinations for
each episode on admission, including WBC count, C-reactive
protein (CRP), serum erythrocyte sedimentation rate (ESR), serum
albumin and total serum protein levels, and WBC count in
peritoneal dialysate; and outcome.
Regarding the peritonitis course, patientswere divided into two
groups: those with curable and those with complicated episodes.
An episode was considered curable if resolution occurred with
antimicrobial therapy, without catheter removal. An episode was
considered complicated if there was relapse or the episode was
repeated, if removal of the catheter took place and/or there was
need for temporary or permanent hemodialysis, and, of course, if
the outcome was fatal. Death was considered peritonitis-asso-
ciated if due to sepsis, if it occurred at the time of a positive
peritoneal dialysis ﬂuid culture, or if it occurred during the
hospitalization period for any patient admitted with peritonitis or
happened within one month following the onset of the infection.5
Episodes due to the same organism with the same sensitivity
pattern occurring during the 4-week period after completion of
antimicrobial therapy were deﬁned as relapses.5 An episode was
considered repeated if due to the same organism with the same
sensitivity pattern, but occurred after the 4-week period following
the completion of therapy.5
Peritonitis was treated intraperitoneally. Initial empiric treat-
ment consisted of vancomycin with an aminoglycoside or,
alternatively, ceftazidime. The dosages used were as per standard
guidelines.8 Subsequent therapy depended on cultures and
sensitivities.
2.1. Statistical analysis
Univariate analyses were ﬁrst conducted to identify potential
risk factors for complicated episodes. The association between two
categorical variables was evaluated by Chi-square test or Fisher’s
exact test as appropriate. For continuous variables, the Student’s t-
test (for normally distributed variables) or the non-parametric
Mann–Whitney test was used to compare the difference in mean
values in the two groups. Variables showing a statistically
signiﬁcant association with complicated course, with a p-value
of <0.05, were considered candidate variables for inclusion in the
multivariate model in order to determine which variables were
independent predictors of a complicated outcome. Stepwise
multivariate logistic regression was performed including the
potential candidate variables.
All analyses were conducted using SPSS version 13.0 (SPSS Inc.,
Chicago, IL, USA). All statistical tests performed were two-tailed;
p < 0.05 was considered as statistically signiﬁcant.
3. Results
During the 17.5-year study period, 247 episodes of PD-
associated peritonitis were identiﬁed in 82 patients. The overall
peritonitis rate was one episode per 14 patient-months or 0.89
episodes per patient-year.The median age of patients was 68 years (range 10–92 years).
There were 51 males (62%) and 31 females (38%). Seventy-four
(90%) had an underlying disease, with the most frequent being
diabetic nephropathy (23 patients; 28%). Fifty-one patients (62%)
were on APD, while 31 (38%) were on CAPD. The median duration
of peritoneal dialysis for all patients was 14 months (range 1–217
months). Demographics are shown in Table 1.
Gram-positive organisms were responsible for 104 episodes
(42%), Gram-negative for 46 (19%), and fungi for 11 (4%). In 13
episodes (5%), peritonitis was polymicrobial, while in 73 (30%)
cultures were negative. The causative organisms are listed in
Table 2.
Staphylococcus epidermidis and Staphylococcus aureus were the
most common Gram-positive organisms, isolated in 48 (46%) and
20 (19%) cases, respectively, while Escherichia coli was the most
common Gram-negative organism and was identiﬁed in eight
cases (17%).
One hundred eighty-three episodes (74%) were cured with the
initial antimicrobial regimen. Sixty-four episodes (26%) were
considered complicated and included 22 (8.9%) relapses, 13 (5.3%)
repeated episodes, 18 (7.3%) catheter removals with temporary or
permanent transfer to hemodialysis, and 11 (4.5%) deaths. The
types of episode and the outcome of all cases are summarized in
Table 3, while the characteristics of the 11 patients with a fatal
outcome are shown in Table 4.
In the univariate analysis, episodes in which antimicrobial
treatment was received at some point in time during the three
preceding months were signiﬁcantly associated with a compli-
cated course, as compared to episodes without prior treatment
(45% vs. 24%; p = 0.001). Furthermore, episodeswhere therewas an
exit-site infectionwere signiﬁcantly associatedwith a complicated
course when compared to episodes without this type of infection
Table 2
Microbiology of peritoneal ﬂuid
Causative organism Number of episodes (%)
Gram-positive organisms (n=104)
Staphylococcus epidermis 48 (46)
Staphylococcus aureus 20 (19)
Corynebacterium spp 8 (8)
Enterococcus spp 6 (6)
Streptococcus mitis 6 (6)
Staphylococcus hominis 5 (5)
Othera 11 (10)
Gram-negative organisms (n=46)
Escherichia coli 8 (17)
Pseudomonas aeruginosa 7 (15)
Enterobacter spp 7 (15)
Klebsiella spp 7 (15)
Acinetobacter spp 4 (9)
Otherb 13 (28)
Fungi (n=11)
Candida albicans 5 (46)
Candida tropicalis 3 (27)
Candida inconspicua 2 (18)
Paecilomyces spp 1 (9)
Polymicrobialc 13 (5)
Culture-negative 73 (30)
a Staphylococcus haemolyticus (2), Staphylococcus simulans (1), Staphylococcus
warneri (1), Streptococcus bovis (1), Streptococcus sanguinis (2), Streptococcus
agalactiae (1), Streptococcus salivarius (1), Streptococcus intermedius (1), Propioni-
bacterium acnes (1).
b Pseudomonas stutzeri (3), Neisseria cinerea (1), Neisseria mucosa (1), Serratia
marcescens (3), Proteus mirabilis (3), Haemophilus aphrophilus (2).
c Corynebacterium group I–Candida parapsilosis; Acinetobacter lwofﬁ–Pseudomo-
nas aeruginosa; Enterococcus faecalis–Candida albicans; Streptococcus intermedius–
Bacteroides spp; Escherichia coli–Enterococcus faecalis; Streptococcus mitis–Enter-
ococcus spp; Staphylococcus warneri–Escherichia coli; Escherichia coli–Proteus
mirabilis; Enterococcus faecalis–Enterococcus faecium; Serratia marcescens–Escher-
ichia coli; Serratia marcescens–Staphylococcus epidermidis; Escherichia coli–Escher-
ichia fergusonii; Klebsiella pneumoniae–Streptococcus salivarius.
Table 3
Type of peritonitis episode and outcome
Number of episodes (%)
Curable episode 183 (74)
Complicated episode 64 (26)
Relapse 22 (8.9)
Catheter removal/transfer to HD 18 (7.3)
Repeated peritonitis 13 (5.3)
Death due to peritonitis 11 (4.5)
Total 247 (100)
HD, hemodialysis.
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previous peritonitis were also associated with a complicated
course when compared to episodes without a history of peritonitis
(61.5% vs. 16.7%; p < 0.001) (Table 5).
Univariate analysis also identiﬁed WBC count, low serum
albumin and total protein on admission, andmore than 5 dayswith
a PD efﬂuent cell count >100  106/l, as signiﬁcantly associated
with a complicated course. Furthermore, patients with a compli-
cated course were hospitalized longer compared to those with an
uncomplicated course (6.7 vs. 3.9, p < 0.001) (Table 5).
There were no statistical differences in the type of peritonitis
course caused by Gram-positive organisms when compared to
those caused by Gram-negative organisms, as well as to those due
to polymicrobial infections. Overall, when fungal peritonitis wasTable 4
Characteristics of patients with a fatal outcome
Case Age at
episode, years
Sex Peritoneal
dialysis duration, months
Initial dia
cell count
1 88 M 18 1230
2 83 M 41 9800
3 63 M 19 3450
4 70 M 0.5 6770
5 89 F 0.5 412
6 42 F 13 8000
7 70 F 40 4400
8 78 M 14 3990
9 76 M 107 1210
10 73 F 70 9800
11 87 F 0.5 334
Mean ( SD) 74.5 (13.3) 29.4 (10.1) 4491 (361
WBC, white blood cell count; M, male; F, female; SD, standard deviation.compared to all other types, a signiﬁcant increase in the incidence
of a complicated course was noted (81.8% vs. 23.3%, p < 0.001).
Logistic regression analysis revealed that the presence of a
purulent exit-site infection (OR 11.321, 95% CI 3.561–35.988;
p < 0.001), peritoneal dialysis efﬂuent cell count >100  106/l for
more than 5 days (OR 1.588, 95% CI 1.311–1.923; p < 0.001), prior
antibiotic use in the 3 months before the episode (OR 3.322, 95% CI
1.389–7.942; p < 0.05), and low serum total protein level on
admission (OR 0.386, 95% CI 0.156–0.957; p < .05) were indepen-
dent predictors of a complicated course (Table 6).
4. Discussion
The results of the present study conﬁrm that peritonitis remains
a serious cause ofmorbidity,mortality, and/or technical failures for
patients maintained on PD therapy, as has been noted in other
studies.2–4
The study also shows that patients treatedwith antimicrobials at
some point in time during the 3-month period preceding the
peritonitis episode, those with an exit-site infection, those with a
peritoneal dialysis efﬂuent cell count >100 106/l for more than 5
days, and those with a low serum total protein level on admission,
areathigh-risk foracomplicatedcourseofPD-associatedperitonitis.
Other researchers have previously found that both the duration
of PD and the number of days that the peritoneal efﬂuent cell count
remains >100  106/l are independent predictors of outcome in
PD-associated peritonitis.10 Our study conﬁrms that a peritoneal
efﬂuent cell count >100  106/l for more than 5 days represents a
bad prognostic factor.
Other studies have reported that recent antimicrobial therapy is
an important risk factor associated with fungal peritonitis11 and
peritonitis due to Pseudomonas species.12 However, our study
suggests that prior antimicrobial therapy during the 3 months
preceding the episode is an independent predictor of a complicated
course. A possible explanation for this result is that the use of
antibiotics alters the body ﬂora and provokes the development of
resistant bacterial strains.13lysate
, 106/l
Days of
cells >100106/l
WBC on
admission, 109/l
Organism
3 15.4 Candida albicans
10 16.7 Klebsiella oxytoca
7 17.0 Negative
6 16.7 Negative
10 15.6 Polymicrobial
12 22.0 Polymicrobial
12 21.0 Polymicrobial
6 17.0 Candida albicans
8 11.5 Staphylococcus aureus
10 17.9 Polymicrobial
8 16.6 Negative
3) 8.3 (2.8) 17.036 (27.73)
Table 5
Factors associated with a complicated course (univariate analysis)
Factor % Complicated episodes if factor present % Complicated episodes if factor absent p-Value
Male gender 43.1 51.6 NS
Urban community 46.15 47.6 NS
Co-morbidity
Diabetes mellitus 38.5 50.0 NS
Hypertension 39.6 55.9 NS
Hyperparathyroidism 37.5 48.5 NS
Diabetic nephropathy 39.1 52.5 NS
History of peritonitis 61.5 16.7 <0.001
Continuous ambulatory peritoneal dialysis 35.5 49 NS
Clinical ﬁndings
Fever 28.7 22.9 NS
Exit-site infection 72.0 20.7 <0.001
Prior antimicrobial use 40.3 20.0 0.001
Curable episodes Complicated episodes
Age at the onset of peritonitis, mean SD 64.1415.44 64.0918.24 NS
Laboratory ﬁndings, mean SD
WBC on admission, 109/l 10.4273.438 12.3383.949 0.001
Albumin on admission g/dl 3.660.54 3.35 0.54 <0.001
Total protein on admission g/dl 6.06 0.66 5.47 0.61 <0.001
Efﬂuent cells on admission  106/l 21292598 31983212 0.003
Days for efﬂuent cells <100106/l 3.68 6.38 <0.001
Days to normalization of WBC 2.11 3.11 0.001
Days of hospitalization 3.9 6.7 <0.001
Duration of peritoneal dialysis therapy (months) 20.25 25.03 NS
Interval between two episodes (months) 8.75 7.91 NS
Number of previous episodes 1.94 2.47 NS
NS, not signiﬁcant; WBC, white blood cell count.
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with an exit-site infection is less likely to respond to antimicrobial
treatment when compared with peritonitis not related to such an
infection.14 Additionally, episodes of peritonitis associated with an
exit-site infection often result in catheter loss and increased
morbidity.8,15 The present study strongly conﬁrms these observa-
tions, since the presence of an exit-site infection was indepen-
dently associated with a complicated course.
Low serum albumin has also been reported to be an adverse
prognostic factor in adults with ESRD on continuous PD,
predisposing to peritonitis.16 In addition, low serum albumin
predicts both mortality and prolonged hospital stay in patients
with PD-associated peritonitis.17 However, in our study, even
though low serum albumin was associated more frequently with a
complicated course on univariate analysis, it was not indepen-
dently associated with a complicated course on multivariate
analysis, as has been reported by others.10
Since long-term chronic PD therapy has been associated with
alterations in peritoneal membrane structure and peritoneal
macrophage function, it was thought that the duration of PD
treatment might be a predictor of a complicated course, although
data are inconclusive. Troidle et al.18 revealed that themortality rate
was equal among patients with different PD therapy durations. On
the other hand, Krishnan et al.10 found that the duration of PD
independentlyandadverselyaffected theoutcomeofperitonitis.We
failed to ﬁnd any relationship between PD duration and outcome.Table 6
Predictors of a complicated course (multivariate analysis)
Variable OR 95% CI p-Value
Prior antimicrobial use (<3 months) 3.322 1.389–7.942 0.007
Presence of exit-site infection 11.321 3.561–35.988 <0.001
Total protein count on admission 0.386 0.156–0.957 0.04
Peritoneal dialysis efﬂuent cell
count >100106/l for >5 days
1.588 1.311–1.923 <0.001
OR, odds ratio; CI, conﬁdence interval.It has been hypothesized that the peritoneal dialysate WBC
count may be an index of peritonitis severity and also predictive
of the response to antimicrobials.19 Indeed, there is a strong
correlation between the number of days with a PD efﬂuent cell
count >100  106/l and a complicated course of peritonitis. In
our study, patients with a PD efﬂuent cell count >100  106/l for
more than 5 days were at increased risk for a complicated course.
The cut-off point of 5 days appears critical, since Krishnan et al.10
also reported the same period as a predictor of complicated
course.
Co-morbid diseases are common in this patient population and
have been shown to predict mortality.20,21 Furthermore, patients
with diabetes mellitus are at high risk for peritonitis.22 However,
our study did not conﬁrm that diabetes mellitus, cardiovascular
disease, heart failure, or secondary hyperparathyroidism could
affect the course of peritonitis. It should be noted that in the
present study the number of patientswithmalignancieswas small,
hence immunodeﬁciency due to disease and/or chemotherapy
could not be associated either with the course or with the outcome
of the infection.
In the present study the outcome of peritonitis in patients on
APD was not different when compared to patients on CAPD. This
lack of difference has been shown by other investigators in the
past.23,24 Sex and age also did not inﬂuence the course and
outcome of peritonitis, although some groups have suggested that
age may be important. Choi et al.25 observed that PD catheter
removal because of peritonitis was more common in elderly
patients, while Perez Fontan et al.9 found that older age is a
signiﬁcant correlate of peritonitis-related mortality.
PD-associated peritonitis is most often due to contamination
with skin ﬂora, with S. epidermidis and S. aureus accounting for the
majority of cases, as was found in the present study.26 However, in
the present patient population, in contrast to earlier observations,
the type of infective organism did not inﬂuence peritonitis
course.8,27 Only cases caused by fungi had a signiﬁcantly more
complicated course, as has been described in previous studies.11 Of
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(30%) in the present study as compared to other series (20%).5
The fatality rate in the present serieswas 4.8%, fallingwithin the
range reported by others (1–6%).9
Our study has the inherent limitations of all retrospective
studies.Wewere unable to discern the effects of patient education,
socioeconomic status, nasal carriage of S. aureus, and nutritional
status on peritonitis course and outcome.
In conclusion, patients with PD-associated peritonitis with an
exit-site infection, a peritoneal dialysis efﬂuent cell count
>100  106/l for more than 5 days, antimicrobial therapy during
the three precedingmonths, and a low serum total protein level on
admission are at high risk for a complicated course. These data
suggest that simple clinical and laboratory ﬁndings remain useful
tools, indicating in a timely manner the severity of the disease.
Further study is needed to determine whether aggressive manage-
ment of these cases improves outcome.
Conﬂict of interest: No conﬂict of interest to declare.
References
1. US Renal Data System. USRDS 2005 annual data report. Bethesda, MD: National
Institutes of Health, Department of Health and Human Services; 2005.
2. Piraino B. Peritonitis as a complication of peritoneal dialysis. J Am Soc Nephrol
1998;9:1956–64.
3. Gokal R. Peritoneal dialysis in the 21st century: an analysis of current problems
and future developments. J Am Soc Nephrol 2002;13:S104–15.
4. Fried L, Bernardini J, Johnston JR, Piraino B. Peritonitis inﬂuences mortality in
peritoneal dialysis patients. J Am Soc Nephrol 1996;7:2176–82.
5. Piraino B, Bailie GR, Bernardini J, Boeschoten E, Gupta A. Peritoneal dialysis-
related infections recommendations: 2005 update. Perit Dial Int 2005;25:107–
35.
6. Kotsanas D, Polkinhorne KR, Korman TM, Atkins RC, Brown F. Risk factors for
peritoneal dialysis-related peritonitis: can we reduce the incidence and
improve patient selection? Nephrology 2007;12:239–45.
7. Daly CD, Campbell MK,MacLeod AM, Cody DJ, Vale LD, Grant AM, et al. Do the Y-
set and double-bag systems reduce the incidence of CAPD peritonitis? A
systematic review of randomized controlled trials. Nephrol Dial Transplant
2001;16:341–7.
8. Bunke CM, Brier ME, Golper T. Outcomes of single-organism peritonitis in
peritoneal dialysis: Gram-negatives versus Gram-positives in the Network 9
peritonitis study. Kidney Int 1997;52:524–9.
9. Perez Fontan M, Rodriguez-Carmona A, Garcia-Naveiro R, Rosales M, Villaverde
P, Valdes F. Peritonitis-related mortality in patients undergoing chronic peri-
toneal dialysis. Perit Dial Int 2005;25:274–84.10. Krishnan M, Thodis E, Ikonomopoulos D, Vidgen E, Chu M, Bargman JM, et al.
Predictors of outcome following bacterial peritonitis in peritoneal dialysis. Perit
Dial Int 2002;22:573–81.
11. Goldie SJ, Kiernan-Troidle L, Torres C, Gorban-Brennan N, Dunne D, Kliger AS,
et al. Fungal peritonitis in a large chronic peritoneal dialysis population: a
report of 55 episodes. Am J Kid Dis 1996;28:86–91.
12. Szeto CC, Chow KM, Leung CB, Wong TY, Wu AK, Wang AY, et al. Clinical course
of peritonitis due to Pseudomonas species complicating peritoneal dialysis: a
review of 104 cases. Kidney Int 2001;59:2309–15.
13. McCormick JB. Epidemiology of emerging/re-emerging antimicrobial-resistant
bacterial pathogens. Curr Opin Microbiol 1998;1:125–9.
14. Golper TA, Brier ME, BunkeM, Shreiber MJ, Bartlett DK, Hamilton RW, et al. Risk
factors for peritonitis in long-term peritoneal dialysis: the Network 9 perito-
nitis and catheter survival studies. Am J Kidney Dis 1996;28:428–36.
15. Gupta B, Bernardini J, Piraino B. Peritonitis associated with exit-site and tunnel
infection. Am J Kidney Dis 1996;23:415–9.
16. Blake PG, Flowerdew G, Blake RM, Oreopoulos DG. Serum albumin in patients
on continuous ambulatory peritoneal dialysis: predictors and correlations with
outcomes. J Am Soc Nephrol 1993;3:1501–7.
17. Trivedi HS, Tan SH, Prowant BF, Sherman A, Voinescu CG, Atalla J, et al.
Predictors of hospitalization in patients on peritoneal dialysis: the Missouri
experience. Am J Nephrol 2007;27:483–7.
18. Troidle L, Gorban-Brennan N, Kliger AA, Finkelstein FO. Effect of duration of
chronic peritoneal dialysis therapy on the development of peritonitis. Perit Dial
Int 1999;19:376–9.
19. Chow KM, Szeto CC, Cheung KK, Leung CB, Wong SS, Law MC, et al. Predictive
value of dialysate cell counts in peritonitis complicating peritoneal dialysis. Clin
J Am Soc Nephrol 2006;1:768–73.
20. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Hypoalbumi-
nemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc
Nephrol 1996;7:728–36.
21. Davies SJ, Phillips L, Naish PF, Russell GI. Quantifying comorbidity in peritoneal
dialysis patients and its relationship to other predictors of survival.Nephrol Dial
Transplant 2002;17:1085–92.
22. Chow KM, Szeto CC, Leung CB, Kwan BCH, Law MC, Li PK. A risk analysis of
continuous ambulatory peritoneal dialysis-related peritonitis. Perit Dial Int
2005;25:374–9.
23. Rodriguez-Carmona A, Perez FM, Garcia FT, Fernandez RC, Valdes F. A com-
parative analysis on the incidence of peritonitis and exit-site infection in CAPD
and automated peritoneal dialysis. Perit Dial Int 1999;19:253–8.
24. Yishak A, Bernardini J, Fried L, Piraino B. The outcome of peritonitis in patients
on automated peritoneal dialysis. Adv Perit Dial 2001;17:205–8.
25. Choi P, Nemati E, Banerjee A, Preston E, Levy J, Brown E. Peritoneal dialysis
catheter removal for acute peritonitis: a retrospective analysis of factors
associated with catheter removal and prolonged postoperative hospitalization.
Am J Kidney Dis 2004;43:103–11.
26. Zelenitsky S, Barris L, Findlay I, Alfa M, Ariano R, Fine A, et al. Analysis of
microbiological trends in peritoneal dialysis related peritonitis from 1991 to
1998. Am J Kid Dis 2000;36:1009–13.
27. Troidle L, Gorban-BrennanN, Kliger A, Finkelstein F. Differing outcome of Gram-
positive and Gram-negative peritonitis. Am J Kidney Dis 1998;32:623–8.
